Clinical Trial

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Study acronym: DEFI-RDEB
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa. Funding Source - FDA OOPD
Protocol Amendment History 24 amendments
This ClinicalTrials.gov record has been amended 24 times since 2019-12-26; most recent amendment 2026-03-16.
Status change: Recruiting → Active, Not Recruiting 2022-08-10
Status change: Not Yet Recruiting → Recruiting 2020-03-27
Trial Details
NCT Number NCT04213261
Lead Sponsor Castle Creek Biosciences, LLC.
Conditions Recessive Dystrophic Epidermolysis Bullosa
Enrollment 6 participants
Start Date 2020-06-09
Primary Completion 2023-01-17 (estimated)
Study Completion 2037-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-18